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Abstract 
We transfected the COS-7 cells with cDNAs encoding different human somatostatin receptor (hSSTR) subtypes, and found that hSSTR subtypes 
mediate not only the inhibition of forskolin-induced CAMP accumulation but also the stimulation of phospholipase C (PLC) and Ca” mobilization. 
Activation of PLC by 1 PM somatostatin (SRIF) was in the order of: hSSTR5 > hSSTR2 > hSSTR3 > hSSTR4>> hSSTR1. Pertussis toxin (PTX) 
treatment completely or partially reversed the PLC activation. 1 nM SRIF was equally effective for adenylate cyclase (AC) inhibition in a 
PTX-sensitive manner, in all the cells expressing different hSSTRs, except for hSSTR1. Nevertheless, SRIF stimulated AC even in the presence of 
forskolin at higher doses of SRIF in PTX-treated hSSTRS~xpre~ing cells. We conclude that the cloned hSSTRs differentially couple to PTX-sensitive 
and -insensitive G-proteins to modulate PLC, Ca*’ mobilization and AC. 
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1. Introduction 
Somatostatin (SRIF), a tetradeca~ptide, exerts a va- 
riety of physiological effects in different organs [l]. For 
example, in central nervous system SRIF acts as a neuro- 
transmitter [2] and neuromodulator, both in an excita- 
tory and inhibitory manner [3,4]. In pituitary and pan- 
creas it is a potent inhibitory regulator of secretory proc- 
esses [l]. Recent studies have demonstrated the antipro- 
liferative effects of SRIF in tumor cells derived from 
different tissues including pituitary, breast and prostate 
[S]. Most, but not all, SRIF actions are sensitive to per- 
tussis toxin (PTX), e.g. PTX treatment diminishes SRIF 
inhibition of the secretion of hormones and enzymes [I], 
but SRIF-induced Na+-H’ exchange and cell growth 
inhibition [7] are not sensitive to PTX 161. These findings 
suggest he coupling of the SRIF receptor to a variety of 
effector systems through PTX-sensitive and -insensitive 
G-proteins, to regulate multiple cellular processes. 
Until now, five subtypes of hSSTR (hSSTR1, 
hSSTR2, hSSTR3, hSSTR4, and hSSTR5) have been 
cloned [8-141. Among them hSSTR2, hSSTR3, and 
hSSTR4 but not hSSTR5 have been reported to couple 
to an inhibitory adenylate cyclase system through PTX- 
sensitive G-proteins [14,15]. Thus, in spite of a variety of 
* Corresponding author. Fax: (8 1) (272) 3 l-61 86. 
Abbreviations: SRIF, somatostatin; PTX, pertussis toxin; hSSTRl-5, 
human somatostatin receptor type 1-5; G-protein, guanine-nucleotide 
binding regulatory protein; Gi and G,, inhibitory and stimulatory 
G-proteins; [Caz+li, cytosolic Ca” concentration. 
SRIF functions, on signal transduction pathways cou- 
pled to the cloned SRIF receptors only the adenylate 
cyclase system has been studied. Hence, it is important 
to investigate the other effector systems uch as phospho- 
lipase C (PLC) and Ca*’ mobilization. Recently, we have 
reported [IS] the activation of the PLC-Ca” system by 
hSSTR1 and hSSTR2. In this study we characterize all 
the other receptor subtypes regarding PLC activation 
and Ca*’ mobilization along with adenylate cyclase mod- 
ulation. In order to better compare some responses we 
used hSSTR I - and hSSTR2-transfe~ted cells. 
2. Materials and methods 
2. I. Materials 
SRIF and forskdin were purchased from Sigma; [‘2SI]Tyr’-SRIF 
(2,200 Ci/mmol) from DuPont-New England Nuclear. PTX was kindly 
provided by Dr. M. Ui (Tokyo Univ.), and the CAMP assay kit was 
from Yamasa Shoyu Co. (Chiba, Japan). The sources of all other 
reagents were the same as described in [15,16]. 
2.2. Ceil culture and DNA tra~fe&tion 
COS-7 cells were cultured and harvested as described in [IS]. All 
expression vectors were constructed as described in [9,13,15] and trans- 
fected in COS-7 cells by eiectroporation as described in [ 15,161. 
2.3. Inositolphosphate assay 
The cells cultured with [‘Hlinositol were washed twice with the 
HEPES-buffered medium composed of 10 mM HEPES (pH 7.5), 134 
mM NaCl, 4.7 mM KCl, 1.2 mM KH,P04, 1.2 mM MgSO,, 2 mM 
CaCI,, 2.5 mM NaHCO,, 5 mM glucose, and 0.1% (w/v) bovine serum 
albumin (fraction V), and then incubated for 1 h at 37°C with the same 
medium containing 10 mM LiCl and the agents to be tested in a final 
volume of 0.5 ml. The reaction was terminated by aspirating the me- 
dium and adding 1.2 ml of 5% perchloric acid. [sH]Inositol phosphates 
including inositol mono-, di- and tri-phosphates were separated on 
Dowex 1 x 8 formate columns as described in [17]. 
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2.4. [Cd+li me~urements 
Cytosolic Ca*+ was estimated by monitoring changes in the fluores- 
cence of Fura- loaded cells as described in [15,16]. 
2.5. Radioimmunoassay of CAMP content 
The cells were washed twice with the HEPES-b~ered medium, and 
incubated for 10 min at 37’C, with the agents to be tested in the 
presence of 100 PM Ro 20-1724 and 50 PM forskolin in all CAMP 
experiments, unless otherwise stated. The reaction was te~inated by 
adding 100 ,ul of 1 N HCl. Measurement of CAMP content was per- 
formed as described in [16]. 
2.6. fi2-‘I]Qr’-SRIF binding 
SRIF binding experiments were performed by the methods as de- 
scribed in [8,15] with slight modifications. Briefly cells were washed 
with the HEPES-buffers medium, and then incubated in the same 
medium with [‘251]Tyr’-SRIF (ca. 40,000 cpm) in the presence of 1.2 nM 
SRIF for 30 min at 25°C. The cells were washed twice with the ice-cold 
HEPES-buffered medium and membrane bound [‘25fjSRIF was ex- 
tracted with 5% trichloroacetic acid (1 ml). Radioactivity in the extract 
was measured by a y-counter. Specific binding was defined as the 
radioactivity displaced by the addition of l.~uM unlabeled SRIF. 
2.7. Data presentations 
All experiments were performed in duplicate or triplicate. The results 
of multiple observations are presented as the mean of results from more 
than three different batches of the cells, unless otherwise stated. 
3. Results 
Fig. 1 shows the typical patterns of 100 nM SRIF- 
induced increase in [Ca2’]i in the cells transfected with 
different SRIF receptor cDNAs. SRIF did not induce 
any [Ca*‘], increase in the cells transfected with plasmid 
vector alone even at 1 /-M concentration, but in all the 
cells transfected with three hSSTR cDNA subtypes, a 
significant increase in [Ca”]i was observed. Such in- 
crease in [Ca2+li was found even at low extracellular Ca*” 
conditions where an excess amount of EGTA was added 
before application of the agonist (data not shown). In 
hSSTRS-expressing cells, the [Ca*‘]i level reached about 
1.5 times the basal value, and was higher than those in 
hSSTR3- and hSSTR4-expressing cells. The net in- 
creases in [Ca2’li by 100 nM SRIF in hSSTRS-, hSSTR3-, 
and hSSTR4-expressing cells were 69.75A6.8, 38.5 22.5 
and 22.5 + 0.5 nM, respectively. 
In order to further characterize the hSSTR-mediated 
[Ca*‘]i increase, we next analyzed PLC activation medi- 
ated by the aforementioned receptor subtypes in compar- 
ison with hSSTR1 and hSSTR2. Fig. 2A shows the inos- 
itol phosphate production by SRIF. In agreement with 
the [Ca*‘]i increases, the inositol phosphate response to 
1 PM SRIF in hSSTRS-expressing cells was higher 
(12 times the basal activity) than those in hSSTR3 and 
hSSTR4-expressing cells (2.7 and 1.7 times, respectively). 
Consistent with previous results fl5], the inositol phos- 
phate response in hSSTRZexpressing cells was much 
higher (10 times the basal activity) than that in hSSTRl- 
expressing cells (1.3 times). Thus, the order of potency 
for SRIF-induced inositol phosphate production was 
hSSTR5 > hSSTR2 > hSSTR3 > hSSTR4 >> hSSTR1. 
As shown in Fig. 2B, PTX treatment of the cells inhib- 
ited PLC activities mediated by all the hSSTR subtypes. 
The inhibition was more obvious at the lower doses of 
SRIF, although in the case of hSSTR4-expressing cells, 
more than 90% inhibition occurred within the whole 
range of SRIF concentrations tested. The inhibition was 
60%, 80% and 90% for 10 nM, and 35%, 55% and 70% 
for 1 ,uM in hSSTRS-, hSSTR2- and hSSTR3-expressing 
cells, respectively (Fig. 2B). 
To rule out the possibility that the quantitative differ- 
ences in effects of the expressed hSSTR subtypes might 
be due to differential expression of receptor proteins on 
the surface of transfected cells, we examined specific 
binding of labeled SRIF on the transfected cells. As 
shown in Fig. 3, at 1.2 nM [‘251]SRIF binding on the cells 
transfected with hSSTRs was in the order of: 
hSSTR1 > hSSTR4 > hSSTR2 > hSSTR5 = hSSTR3. 
These results confirm clearly the higher efficacy of 
hSSTR5- and hSSTRZexpressing cells, when compared 
to hSSTR1 and hSSTR4 in coupling to the PLCfCa*’ 
signaling pathway. 
Concurring with our previous study [15], SRIF inhib- 
800 
pCMV6c hSSTR3 hSSTR4 hSSTR5 
200 L. t t t t 
1 Min 
Fig. 1. Representative traces of the [Ca”], changes produced by SRIF (100 nM) added at the sites indicated by arrows in pCMW+transfected, 
hSSTR3-, hSSTRC, and hSSTRS-expressing, Fura 2-loaded cells. 
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Fig. 2. Dose-dependent effect of SRIF on inositol phosphate produc- 
tion (including mono-, di-, and triphosphates) in pC~V~-transf~ted 
(A), hSSTR1 (a)-, hSSTR2 (o)-, hSSTR3 (d-, hSSTR4 (a)-, and 
hSSTR5 (C)-expressing cells, untreated (A) and treated (B) with PTX 
(100 &ml, for I8 h before assays). Insets in A and B show the same 
activity (except hSSTR2 and hSSTR5) at an enlarged scale. The results 
are shown as mean + S.E.M. of three different experiments performed 
in triplicate and expressed as percentage of the control value without 
SRIF, taken as 100%. 
ited forskolin-induced CAMP accumulation in cells 
transfected with plasmid vector alone, showing that the 
cells contain some native low affinity SRIF receptors 
(Fig. 4A). On the other hand, we found an efficient cou- 
pling of hSSTR3, hSSTR4, and hSSTR5 to the adenylate 
cyclase system. SRIF dose-dependently inhibited fors- 
kolin-induced CAMP accumulation in the cells trans- 
fected with hSSTR3, hSSTR4, and hSSTR5, even at low 
doses of SRIF (0.1-I nM) (Fig. 4B,C,D). Surprisingly, 
however, the inhibitory effect mediated by hSSTR5 was 
significantly reduced with the increase in SRIF concen- 
trations above 10 nM. 
PTX treatment of the transfected cells completely 
abolished the inhibitory effect of SRIF on the forskolin- 
induced cAMP accumulation in the hSSTR3-and 
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hSSTR4-expressing cells as well as in the cells transfected 
with vector alone. Interestingly, in the cells expressing 
hSSTR5, in addition to the complete abolition of the 
inhibitory effect, there was a further increase in CAMP 
accumulation in response to SRIF, especially at higher 
doses. 
4. Discussion 
In our COS-7 cell expression system, as we reported 
recently [15], hSSTR2, and to a lesser extent hSSTR1, 
induced activation of PLC and Ca” mobilization. We 
now are able to report the characterization of the other 
hSSTR subtypes, hSSTR3, hSSTR4, and hSSTR5, and 
their responses to SRIF, which are compared with those 
of hSSTR1 and hSSTR2. As shown in Fig. 2, maximum 
activation of PLC at 1 ,uM SRIF was in the order of 
hSSTR5 > hSSTR2 > hSSTR3 > hSSTR4 >> hSSTR1, 
in a PTX-sensitive manner. However, the mode of inhibi- 
tion caused by PTX was dependent upon the species of 
receptor subtype and the SRIF dose employed. Thus, all 
the hSSTR subtypes mediate the SRIF activation of PLC 
preferentially through a PTX-sensitive pathway at lower 
doses of SRIF, but hSSTR2, hSSTR3, and hSSTR5 also 
are able to do so through a PTX-insensitive pathway at 
higher doses. Analogically to the other seven-transmem- 
brane type receptors coupled to PLC, the PTX-sensitive 
and -insensitive pathways probably involve GJG, and 
G, (or other members of its family), respectively [18]. 
Taken together, these results suggest hat all the hSSTR 
subtypes preferentially couple to G,/G, at lower doses of 
1.0, 
Fig. 3. Specific binding of [‘2SI}Tyr’-SRIF to pCMV6c-transfected, 
hSSTR l-, hSSTR2-, hSSTR3-, hSSTR4-, and hSSTRS-expressing cells 
in 6-well plates (about 100 pg cell protein) were incubated with 
[‘*‘I]SRIF in the presence of 1.2 nM SRIF. Results were normalized and 
specific binding (pmol/mg of protein) was expressed as mean f S.E.M. 
of four values from two separate xperiments. 
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Fig. 4. Dose-dependent effect of SRIF on forskohn-induced CAMP 
accumulation in pCMV6c-transfected (A), hSSTR3- (B), hSSTR4- (C), 
and hSSTR5- (D) expressing cells, untreated (0) and treated (0) with 
PTX (100 t&ml for 18 h before assay). The results are shown as 
mean f S.E.M. of three separate xperiments performed in triplicate. 
SRIF, but hSSTR2, hSSTR3 and hSSTR5 can also cou- 
ple to G, to activate PLC at higher doses. This conclu- 
sion is supported by the fact that the lower doses of SRIF 
(at 0.1-l nM) inhibited adenylate cyclase in a PTX- 
sensitive manner in hSSTR3-, hSSTR4-, and hSSTRS- 
(Fig. 4) as well as in hSSTRZexpressing cells [15]. 
Raynor et al. [14] have reported that SRIF did not 
inhibit CAMP accumulation either in COS-1, CHO- 
DG44, or in CHO-I(1 cells expressing hSSTR5, but in 
our COS-7 cell expression system, we could detect a 
significant inhibitory effect of SRIF. This discrepancy 
between our results and Raynor’s might be due to the 
differences in the amount and species of G-proteins ex- 
pressed in COS-7 cells from those in the cell types exam- 
ined by them. Even in our study, however, the CAMP 
response pattern seems to be odd. The inhibitory effect 
on the forskolin-induced CAMP accumulation was ap- 
preciably reduced at higher doses of SRIF. Furthermore, 
in PTX-treated cells, the inhibitory effect of SRIF on 
forskolin-induced CAMP accumulation was completely 
abolished, and in contrast, the high CAMP level obtained 
by forskolin was further increased in response to SRIF 
(Fig. 4D). We also found that in the absence of forskolin, 
SRIF did not inhibit but stimulated CAMP accumulation 
in a dose dependent manner (data not shown). The po- 
tency of SRIF in the reaction was similar to that in the 
induction of inositol phosphate response (data not 
shown), suggesting that hSSTR5 can link to the adenyl- 
ate cyclase system as a stimulator in addition to inhib- 
itory role at the higher doses of SRIF. We have no direct 
evidence showing the coupling of hSSTR5 to G,. When 
the COS-7 cells were transfected with muscarinic recep- 
tor type 3, which is known to couple to a PTX-insensitive 
G-protein to activate PLC, but not to G,, carbachol 
increased not only inositol phosphate production to a 
similar extent as that induced by SRIF but also CAMP 
a~umulation, although to a lesser extent than in the case 
of SRIF (data not shown). Among several subtypes of 
adenylate cyclases, type 2, 5 and 6 have been shown to 
be activated by receptors coupled to PLC through pro- 
tein kinase C activation and Ca2’ mobilization [ 181. Such 
a mechanism might at least in part be involved in SRIF- 
induced CAMP a~umulation in hSSTRS-expressing 
cells. 
In a few studies, SRIF activated PLC followed by Ca” 
mobilization in native SRIF receptor-expressing cells 
such as striatal astrocytes [19] and NG 108-15 [20]. The 
requirement of Ca2’-dependent phospholipase A2 activa- 
tion also has been postulated in SRIF actions in hip- 
pocampal cells [21]. Since SRIF exerts excitatory as well 
as inhibitory effects on neurons [4], activation of PLC 
and related responses may account for the excitation of 
somatostatinergic neurons in central nervous system. 
Our findings in the present study suggest hat cloned 
human SRIF receptor subtypes, when transfected in 
COS-7 cells, not only modulate the adenylate cyclase 
system but also couple to PTX-sensitive and -insensitive 
G-proteins to stimulate PLC and Ca2+ mobilization, pro- 
viding a new insight into the transducing cascade in var- 
ious physiological events. 
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